Compare Hims and Hers Health Inc (HIMS) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs ING Groep NV — how do they compare? Hims and Hers Health Inc trades at $30.7 (market cap $7.35B), while ING Groep NV trades at $35.34 (market cap $101.24B). The key difference: ING Groep NV is far larger — about 13.8× Hims and Hers Health Inc's market cap, and ING Groep NV pays a 3.74% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | ING | |
|---|---|---|
Market Cap | $7.35B | $101.24B |
Sector | Health | Financials |
52-Week High | $62.76 | $35.92 |
52-Week Low | $14.52 | $23.66 |
Enterprise Value | $7.73B | — |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
ING trades at $35.68, down slightly by 0.08% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79 versus $0.75 expected, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 10 buy ratings and no sell ratings out of 16 analysts.
The outlook for ING is favorable, supported by earnings momentum and strategic initiatives, though risks include negative cash flow trends and potential market volatility. The stock presents a value opportunity with a P/E of 13.37 and a net income margin of 28.34%, but investors should weigh the persistent cash flow deficits against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
